FDA inspectors warn NuVasive on marketing for Affix spinal implants

March 19, 2013 by Arezu Sarvestani

NuVasive explains that an FDA Warning Letter following an inspection at a California manufacturing facility reflects only an issue with marketing – not with any quality systems.

NuVasive logo

Federal regulators warned NuVasive (NSDQ:NUVA) this month about certain promotional claims made in connection with the company's spinal products.

The FDA in October 2012 inspected NuVasive's San Diego, Calif., manufacturing facility, finding only the single violation regarding marketing language for the company's Affix Spinous Process Plate System.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp